A Phase 1a, Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of a Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers

This is a Phase 1a, first in human study in which healthy adult participants who are
considered to be at low-risk for HIV infection and are seropositive for cytomegalovirus (CMV)
will receive two doses of VIR-1111 or placebo. These participants will be assessed for
safety, reactogenicity, tolerability and immunogenicity. There is an optional long-term
follow-up study that would lengthen study participation for up to 3 years post-first dose.